scholarly journals Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer?

2016 ◽  
Vol 36 (10) ◽  
pp. 5019-5024 ◽  
Author(s):  
CHRISTOS DAMASKOS ◽  
SERENA VALSAMI ◽  
ELEFTHERIOS SPARTALIS ◽  
EFSTATHIOS A ANTONIOU ◽  
PERIKLIS TOMOS ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Novel Therapeutic

scholarly journals Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

2009 ◽  
Vol 94 (1) ◽  
pp. 164-170 ◽  
Author(s):  
Jennifer A. Woyach ◽  
Richard T. Kloos ◽  
Matthew D. Ringel ◽  
Daria Arbogast ◽  
Minden Collamore ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Histone Deacetylase ◽  
Differentiated Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Severe Thrombocytopenia ◽  
Minor Bleeding ◽  
Clinical Grade ◽  
Medullary Thyroid ◽  
Advanced Thyroid Cancer ◽  
Grade 3

Abstract Context: Aberrant histone deacetylase activity is seen in a variety of malignancies, and histone deacetylase inhibitors such as vorinostat have been shown to induce cell death and sensitize cells to cytotoxic chemotherapy in thyroid cancer cell lines. This phase II study was undertaken to assess objective response to vorinostat in patients with advanced thyroid cancer. Experimental Design: A total of 19 patients with differentiated thyroid cancer (n = 16) and medullary thyroid cancer (n = 3) were enrolled in the study. Patients received oral vorinostat at a starting dose of 200 mg twice daily, with dose adjustments allowed as necessary for toxicity. Patients were treated for 2 wk, followed by 1 wk off therapy (3-wk cycle) until disease progression or study withdrawal. Responses were measured by Response Evaluation Criteria in Solid Tumors criteria and correlated with tumor markers. Results: No patient achieved a partial or complete response. Median duration of therapy in patients with differentiated thyroid cancer was 17 wk, whereas in medullary thyroid cancer patients it was 25 wk. Reasons for termination included progression of disease by RECIST criteria (n = 7), clinical progression (n = 3), and adverse events (AEs) (n = 9). AEs were primarily grade 1–3; no clinical grade 4 or grade 5 events were observed. Clinical grade 3 AEs consisted of fatigue, dehydration, ataxia, pneumonia, bruises, and deep vein thrombosis. Severe thrombocytopenia was seen in seven patients (grade 3, n = 5; grade 4, n = 2) and was associated with minor bleeding or bruises. Conclusions: Vorinostat at this dose and schedule is not an effective treatment for advanced thyroid cancer.

scholarly journals Update on Targeted Therapy in Medullary Thyroid Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Christian Okafor ◽  
Julie Hogan ◽  
Margarita Raygada ◽  
Barbara J. Thomas ◽  
Srivandana Akshintala ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Targeted Therapy ◽  
Progressive Disease ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Mechanisms Of Resistance ◽  
Medullary Thyroid ◽  
Resistant Disease ◽  
Sporadic Cases ◽  
Novel Therapeutic

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of RET-targeting tyrosine kinase inhibitors (TKIs) has provided effective options for systemic therapy for patients with metastatic and progressive disease. However, patients that develop resistant disease as well as those with other molecular drivers such as RAS have limited options. An improved understanding of mechanisms of resistance to TKIs as well as identification of novel therapeutic targets is needed to improve outcomes for patients with MTC.

scholarly journals Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer

Surgery ◽  
2018 ◽  
Vol 163 (1) ◽  
pp. 104-111 ◽  
Author(s):  
Irene Lou ◽  
Scott Odorico ◽  
Xiao-Min Yu ◽  
April Harrison ◽  
Renata Jaskula-Sztul ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Therapeutic Target ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Novel Therapeutic

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Sign in / Sign up

Export Citation Format

Share Document